Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
AMGN
Amgen
$281.22
Login to display Amgen (AMGN) recommendation from the last 90 days from financial news and social media.
AMGN Total Score
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Trading below its fair value
Outperform the market
Chart
312.47
This Indicator assigning AMGN risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.
Risk Volatility
AMGN has Low Risk Level
Click here to check what is your level of risk
AMGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
Outperform the market
AMGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AMGN Street view is extremely bullish and have positive views on the near-term outlook
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
AMGN
Amgen
$281.22
Chart
312.47
AMGN Latest Headlines
Amgens Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data. ) reported first-quarter sales of $8.15 billion on Thursday u.Product sales grew 11% primarily driven by 14% volume growth partially offset by 6% lower net selling price. United States sales rose 14%.Fourteen products delivered at least double-digit sales growth in the first quarter.The launch of Imdelltra (tarlatamab-dlle) Amgen reported adjusted EPS of $4.90 up 24% beating.The company also announced a P
Today
Notable Friday Option Activity: AMGN DAL GDDY. Among the underlying components of the S&.P 500 index we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN) where a total of 13443 contracts have traded so far representing approximately 1.3 million underlying shares. That amounts to about 41.7% of A
Today
Amgen Unusual Options Activity For May 02. Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in AMGN usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'.s options scanner
Today
Amgens Q1 Earnings Beat Estimates Key Drugs Drive Sales Growth. AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products Prolia Xgeva Repatha Blincyto and Evenity beat estimates.
Today
Amgen beats top-line and bottom-line estimates. reaffirms FY25 outlook.
Thu May 1, 2025
Amgen quarterly profit tops Wall Street view sales up 11%.
Thu May 1, 2025
Looking At Amgens Recent Unusual Options Activity. Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:) revealed 8 unusual trades.Delving into the details we found 12% of traders were ish while 37% showed bearish tendencies. Out of all the trades we spotted 4 were puts with a value of $128590 and 4 were calls valued at $1226500.Analyzing the Volume and Open Interest in these contracts it seems that the big players have been eyeing a
Wed Apr 30, 2025
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?. Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wed Apr 30, 2025
Amgen to spend $900M to expand Ohio drugmaking plant.
Fri Apr 25, 2025
AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION CREATION OF 350 NEW JOBS IN OHIO. Total Investment in the State to Exceed $1.4 Billion 750 United States Jobs THOUSAND OAKS Calif. April 25 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its Ohio manufacturing facility bringing the total number of jobs created to 750 and the total...
Fri Apr 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AMGN Stock trends
AMGN Stock performance
AMGN Stock analysis
AMGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
